Table III.
Recurrence-free survival | Distant metastasis-free survival | Overall survival | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
95% CI | 95% CI | 95% CI | ||||||||||
Variable | HR | Lower | Upper | P-value | HR | Lower | Upper | P-value | HR | Lower | Upper | P-value |
Periostin expression | 3.450 | 1.240 | 9.603 | 0.018a | 2.305 | 1.111 | 4.781 | 0.025a | 2.298 | 1.013 | 5.213 | 0.047a |
Age | 0.992 | 0.952 | 1.035 | 0.721 | 1.014 | 0.986 | 1.042 | 0.339 | 1.027 | 0.999 | 1.056 | 0.061 |
Tumor size | 5.569 | 1.616 | 19.194 | 0.007a | 1.244 | 0.588 | 2.630 | 0.569 | 0.935 | 0.414 | 2.112 | 0.872 |
Histological grade | 1.128 | 0.378 | 3.366 | 0.829 | 1.535 | 0.723 | 3.259 | 0.265 | 2.435 | 1.030 | 5.759 | 0.043a |
Nodal status | 1.609 | 0.566 | 4.575 | 0.373 | 3.169 | 1.421 | 7.067 | 0.005a | 3.986 | 1.618 | 9.823 | 0.003a |
Phenotype | 0.226 | 0.079 | 0.644 | 0.005a | 1.187 | 0.636 | 2.215 | 0.590 | 0.998 | 0.533 | 1.866 | 0.994 |
ER status | 0.190 | 0.029 | 1.232 | 0.082 | 1.362 | 0.291 | 6.376 | 0.695 | 0.259 | 0.042 | 1.611 | 0.147 |
PR status | 1.044 | 0.191 | 5.723 | 0.960 | 1.002 | 0.335 | 2.999 | 0.997 | 2.959 | 0.795 | 11.015 | 0.106 |
HER2 status | 0.738 | 0.248 | 2.196 | 0.585 | 0.801 | 0.342 | 1.877 | 0.610 | 0.918 | 0.374 | 2.253 | 0.851 |
Ki-67 expression | 8.800 | 1.623 | 47.731 | 0.012a | 1.078 | 0.452 | 2.573 | 0.865 | 0.336 | 0.138 | 0.816 | 0.016a |
P<0.05. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, ErbB2 receptor tyrosine kinase 2.